Variable importance was determined using two measures.
Factor importance was determined using the broken stick distribution.
Discriminant variables were determined using VIP (variable importance in the projection), an appropriate quantitative statistical parameter ranking the descriptors according to their ability to discriminate different doses.
The specific metabolites contributing most significantly to the differences identified by PLS-DA between MuRF2−/− and wildtype control group hearts were determined using the variable importance in projection (VIP) analysis in the Metaboanalyst 2.0 environment.
The specific metabolites contributing most significantly to the differences identified by PLS-DA between MuRF3−/− and wildtype control group hearts were determined using the variable importance in projection (VIP) analysis in the metaboanalyst environment.
Insertion sites were determined using semirandom PCR [31].
Protein concentrations were determined using RC DC Protein Assay (BioRad).
Clusters were determined using Statgraphics Plus 5.0.
Alleles were determined using CEQ Fragment Analysis software.
Private alleles were determined using GDA [40].
